White Bear Lake, MN - Francesco Autuori, President, Chemi S.p.A., Milan, Italy, has announced that Chemi Nutra has begun to aggressively defend its intellectual property related to the manufacture of soy-derived phosphatidylserine (PS). The family of patents (United States Patent Numbers 5,700,668; 6,492,146; 6,645,742) describe a solvent-free, water based process, as well as the development of original purification procedures, collectively representing major industrial innovations for the manufacture of PS. By utilizing these proprietary production methods, Chemi Nutra’s PS is superior in quality to PS manufactured with other methods.
Chemi Nutra’s PS is currently manufactured in Chemi’s pharmaceutical facilities located in Patrica, Italy, and Camacari, Brazil, under strict cGMP guidelines, and both plants are inspected at routine intervals by the US FDA.
“For more than ten years, Chemi has made substantial investments in both technology and commercial production advancements for PS, and our intellectual property has helped to position our branded SerinAid® PhosphatidylSerine (PS) as a high quality, cost competitive, market leader. I am very pleased that we are now taking a strong stand to uphold our valuable PS patents. Nutrition companies who purchase PS should make certain that the PS they acquire from alternate sources is not manufactured using methods contained in Chemi’s patents,” said Scott Hagerman, president of Chemi Nutra.
Chemi Nutra is the US business unit of parent company Chemi S.p.A., a privately held pharmaceutical and nutraceutical company based in Milan, Italy. Chemi, with cGMP certified manufacturing facilities in Italy and Brazil, is best known in the US nutritional arena for its introduction of phosphatidylserine (PS), the popular dietary supplement which has been granted two health claims by the FDA, and is used to enhance learning, memory, and concentration.
-- End --